Generic name: Imatinib mesylate (produced by an Indian company. Commonly known as: Indian Gleevec) Scientific name: English name: Specifications: Tablets/bottle Chinese Pinyin:
Because the product produced by an Indian company is not available in China The Encyclopedia of Drugs Illegal in China approved by the Food and Drug Administration is for annotation purposes only. The following introduction is an introduction to Gleevec, not a complete introduction. Gleevec in India is a common name for uninformed users.
. Gleevec
(Imatinib mesylate) is a new generation of targeted anti-cancer drug that inhibits platelet-derived growth factor (D) receptor protein kinase. Gleevec is the most effective of all anti-tumor drugs. Gleevec is more than 100% effective in the treatment of newly diagnosed chronic myelogenous leukemia and can achieve cytological remission in % of patients.
.
. Gleevec (r imatinib mesylate
) is packaged as tablets per bottle. Each tablet contains. Imatinib mesylate is equivalent to imatinib Ni free base. Medicines are packaged in white polyethylene bottles.
. The results of the Phase III clinical trial show that the effective rate of Gleevec in the treatment of newly diagnosed chronic myelogenous leukemia exceeds 10%, and % of patients can obtain cytological remission. The effective rate of Gleevec in the accelerated phase and blast phase is also reached % and % respectively. The effective rate of Gleevec against gastrointestinal stromal tumors is also as high as %.
. Indications:
. Gleevec (imatinib mesylate) is used to treat newly diagnosed Philadelphia chromosome-positive (+) adults with chronic myelogenous leukemia in the chronic phase.
. Gleevec (imatinib mesylate) is used to treat Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase and accelerated phase. Imatinib mesylate is also used to treat patients who have been interfered with. Chronic myelogenous leukemia in the chronic phase that has been treated with antibiotics.
. Gleevec (imatinib mesylate) is also used to treat pediatric chronic myelogenous leukemia that has relapsed after myelosuppression or has failed to respond to interferon therapy.
. Gastrointestinal stromal tumor
. Gleevec (imatinib mesylate) is used to treat (D)-positive inoperable or metastatic malignant gastrointestinal stromal tumors!
. Main toxic and side effects The most common toxic and side effects include: superficial edema, malignancy and vomiting, muscle aches, muscle cramps, rash and diarrhea.
. Hematologic toxicities including neutropenia and thrombocytopenia are common side effects of Gleevec (imatinib) treatment, but they occur less frequently in newly diagnosed CML patients.
< . -.
Gleevec purchase agent in India, Gleevec price, veenat specific drug